Antibody therapy for relapsed T-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new experimental antibody therapy for people with certain types of peripheral T-cell lymphoma that have not responded to or have come back after prior treatment. The study aims to see if the treatment is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of peripheral T-cell lymphoma (PTCL) that has come back or not responded to at least one prior treatment.
- You have a tumor that can be seen on a scan (at least 1.5 cm in a lymph node or 1 cm elsewhere).
- You are feeling well enough to be up and about (ECOG performance status 0 or 1).
- Your blood counts and organ function are adequate (e.g., hemoglobin ≥8.0, platelets ≥50,000, kidney and liver tests within limits).
- You are willing to provide a bone marrow sample and follow study procedures, including contraception.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing several new drug combinations for people with peripheral T-cell lymphoma that has come back or not responded to treatment. It aims to find new options that may work better.
This trial tests a combination of three drugs (zeprumetostat, azacitidine, and a liposomal form of mitoxantrone) for people with a type of lymphoma called peripheral T-cell lymphoma that has come back or not responded to treatment. The goal is to see if this combination can help shrink or control the lymphoma.
This trial tests a combination of three medicines (anti-PD-1, lenalidomide, and azacitidine) for adults with relapsed or refractory peripheral T-cell lymphoma (PTCL) that is measurable or growing. It aims to shrink lymphoma and improve control of the disease when standard treatments haven’t worked or have stopped working.
This trial is testing a combination of two targeted drugs (linperlisib and an EZH2 inhibitor) for people whose peripheral T-cell lymphoma has come back or not responded to previous treatment. The goal is to see if this new combination can help shrink tumors and slow the disease.
This trial tests if giving a tailored treatment after first complete remission can improve outcomes for certain types of peripheral T-cell lymphoma. It is for people who have finished initial standard chemotherapy with a complete response.
This trial tests a combination of belinostat (a targeted drug) plus either azacitidine or pralatrexate for people with relapsed or refractory T-cell lymphoma. The goal is to find a new treatment option when previous therapies have stopped working.
Hear when a new Peripheral T Cells Lymphoma (PTCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.